Therapeutic Solutions International Provides Correction Re Prior Release

Rhea-AI Summary

Therapeutic Solutions International (TSOI) clarified a previous statement regarding the Principal Investigator for its clinical trial. Dr. James Veltmeyer has been appointed as the Principal Investigator pending FDA approval of TSOI as the trial's sponsor. Additionally, TSOI clarified that JadiCell adult stem cells are derived from umbilical cords and classified as mesenchymal-like stromal cells. The company focuses on immune modulation treatments for various diseases, with a commitment to advancing their clinical research.

Positive

• Appointment of Dr. James Veltmeyer as Principal Investigator could enhance clinical trial credibility.
• Clarification on JadiCell stem cells provides clearer information on product offerings.

Negative

• None.

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International announced today the correction of a statement made in a press release dated March 25, 2022, that said, among other things, that: “As part of the trial organization, the Principal Investigator has been changed to Dr. James Veltmeyer and Therapeutic Solutions International, Inc as the Sponsor.” We wish to clarify that the Board of Directors of TSOI has offered and Dr. Veltmeyer has accepted to be the Principal Investigator of the Clinical Trial upon FDA approval of TSOI as sponsor. In addition to clarify, “JadiCell adult stem cells” are umbilical cord derived mesenchymal like stromal cells also referred to as adult stem cells.^1-5

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

References

1. Jackson KA, Majka, S. M., Wang, H., Pocius, J., Hartley, C. J., Majesky, M. W., Entman, M. L., Michael, L. H., Hirschi, K. K., and Goodell, M. A. : Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001, 107:1395-1402.
2. Slavin S, Kurkalli BG, Karussis D: The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg 2008.
3. Hafizi, M., et al., Exploring the enkephalinergic differentiation potential in adult stem cells for cell therapy and drug screening implications. In Vitro Cell Dev Biol Anim, 2012. 48(9): p. 562-9.
4. Worsham, D.N., et al., In vivo gene transfer into adult stem cells in unconditioned mice by in situ delivery of a lentiviral vector. Mol Ther, 2006. 14(4): p. 514-24.
5. Vaes, B., et al., Culturing protocols for human multipotent adult stem cells. Methods Mol Biol, 2015. 1235: p. 49-58.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005772/en/

Tim G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International

FAQ

What is the recent announcement from Therapeutic Solutions International (TSOI)?

TSOI announced the appointment of Dr. James Veltmeyer as Principal Investigator for its clinical trial, pending FDA approval.

What are JadiCell adult stem cells according to TSOI's clarification?

JadiCell adult stem cells are umbilical cord-derived mesenchymal-like stromal cells.

When was the press release regarding TSOI's clarification issued?

The press release was issued on March 30, 2022.

How does TSOI plan to treat diseases?

Therapeutic Solutions International focuses on immune modulation for the treatment of several specific diseases.